Portola Pharmaceuticals Inc (NASDAQ:PTLA) CEO William Lis sold 30,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $20.83, for a total transaction of $624,900.00. Portola Pharmaceuticals Inc (NASDAQ:PTLA) weekly performance is 12.43%. On last trading day company shares ended up $22.88. Analysts mean target price for the company is $38.50. Portola Pharmaceuticals Inc (NASDAQ:PTLA) distance from 50-day simple moving average (SMA50) is -4.56%.
DARA BioSciences, Inc (Nasdaq:DARA) making a sharp move higher after falling from levels around $3 at the start of 2014. DARA Biosciences Inc (NASDAQ:DARA) shares advanced 98.18% in last trading session and ended the day on $2.18. Gross Margin is 50.00 % and its return on assets is -107.20%. DARA Biosciences Inc (NASDAQ:DARA) quarterly performance is -27.0 %.
On May 21, Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, announced its unaudited first quarter financial results for the period ended March 31, 2014. Quarterly sales increased by 34.8% to $13.5 million from $10.1 million. Gross profit increased by 45.4% to $10.3 million from $7.1 million. Gross margin was 75.8%, compared to 70.2%. Net income attributable to common stockholders was $4,000, or $0.00 per basic and diluted share, compared to a net loss attributable to common stockholders of $2.0 million, or $0.04 per basic and diluted share. Cash and cash equivalents totaled $101.7 million as of March 31, 2014, compared to $107.2 million as of December 31, 2013. Sinovac Biotech Ltd. (NASDAQ:SVA) shares moved up 5.97% in last trading session and was closed at $6.39, while trading in range of $6.04 – $6.45. Sinovac Biotech Ltd. (NASDAQ:SVA) year to date (YTD) performance is 4.41%.
On May 1, OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) was downgraded by analysts at UBS AG from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Tuesday, Stock Ratings Network reports. They currently have a $4.50 price target on the stock, down from their previous price target of $19.00. UBS AG’s price objective would indicate a potential upside of 15.98% from the company’s current price. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) ended the last trading day at $4.12. Company weekly volatility is calculated as 7.16% and price to cash ratio as 1.62. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) showed a positive weekly performance of 8.42%.
BioTime, Inc. (NYSEMKT:BTX) and its subsidiary Asterias Biotherapeutics, Inc. (“Asterias”), announced that Asterias has entered into a settlement agreement with ViaCyte, Inc. (“ViaCyte”) concerning certain litigation in the United States District Court for the Northern District of California (Civil Action No. C12-04813) seeking the reversal of two adverse determinations by the United States Patent & Trademark Office with respect to two patent applications in U.S. Patent Interference 105,734, involving U.S. patent 7,510,876 (ViaCyte) and U.S. patent application 11/960,477 (Geron), and U.S. Patent Interference 105,827 involving U.S. patent 7,510,876 (ViaCyte) and U.S. patent application 12/543,875 (Geron), along with four Opposition Proceedings pending before the Australian Patent Office pertaining to priority rights and the validity of each party’s patents relating to endodermal precursor cells. BioTime, Inc. (NYSEMKT:BTX) weekly performance is 14.71%. On last trading day company shares ended up $2.73. BioTime, Inc. (NYSEMKT:BTX) distance from 50-day simple moving average (SMA50) is -3.25%.